Expected triggers over short to medium term
• Normalisation of ABTS demand
• Completion of capacity expansion for ABTS
• NCLT approval for VAPL merger (currently owned by promoters)
• Ramp up in Anti-oxidants business under VAPL
• Operationalization of capacity under the subsidiary company VOPL (having MEHQ, guaiacol, isoamylene products)
• Revenue diversification due to above mentioned products
Key Risks
• While capex is already delayed, any further delay in capex could be negative
• Also, delay in normalisation of ABTS demand could be another over hang
Disc: Invested. I am not SEBI registered Advisor/Analyst. The information provided above is for education purpose only.
| Subscribe To Our Free Newsletter |
